OpenCareby Vivonco
Search/
Talk to us Review a case
Menu
Skip to content
No. 35 · Thursday, November 12, 2026

FDA approves kinase inhibitor for tenosynovial giant cell tumor

  1. FDA approves kinase inhibitor for tenosynovial giant cell tumor
  2. Personalized therapy intismeran reduced recurrence in skin cancer
  3. The bispecific antibody anbenitamab improved control of breast cancer
  4. TROP2 measure predicted outcomes with the antibody-drug conjugate datopotamab deruxtecan in lung cancer
  5. Immunotherapy added to radiation did not help early-stage lung cancer
  6. The targeted drug risovalisib shrank ovarian cancer in a phase 2 trial
  7. Guidelines recommend molecular testing for children with solid tumors
Read this first · Approved

FDA approves kinase inhibitor for tenosynovial giant cell tumor

The FDA approved the kinase inhibitor pimicotinib for adults with symptomatic tenosynovial giant cell tumor when surgery could cause serious harm. In a trial, tumors shrank in 56% of people taking pimicotinib, compared with 3% taking placebo.

“The prescribing information includes warnings and precautions for hepatotoxicity, embryo-fetal toxicity, and increased serum creatinine without affecting renal function. “TGCT can profoundly affect patients' daily lives through persistent pain, swelling, and loss of joint function,” said Sydney Stern, PhD, MS , TGCT Support, a Program of the Life Raft Group. “For symptomatic patients who are not likely to benefit from surgery alone, there remains need for treatment options which are tolerable and effectively address the burden of disease, shrink their TGCT, and improve pain and function.””

Why it matters. Approved by the US Food and Drug Administration (FDA). Doctors can now prescribe it outside a trial.

The ASCO Post, 10 Nov 2026 · Regulatory approval Worth sharing · Share on X · Email a friend
Phase III trial · melanoma, a skin cancer

Personalized therapy intismeran reduced recurrence in skin cancer

In a phase 3 trial, people with high-risk skin cancer removed by surgery received pembrolizumab with personalized therapy intismeran or placebo. At 24 months, 82.2% of the intismeran group had no recurrence, compared with 70.0% of the placebo group.

“Adjuvant therapy (given after surgery) with intismeran plus pembrolizumab significantly prolonged recurrence-free survival and distant-metastasis-free survival as compared with pembrolizumab alone in patients with completely resected, high-risk cutaneous melanoma.”

Why it matters. People with high-risk skin cancer removed by surgery may have less risk of recurrence and spread with personalized therapy added to pembrolizumab. Results from a large final-stage trial like this decide approvals.

New England Journal of Medicine, 11 Nov 2026 · Phase III human clinical trial | 1137 patients Worth sharing · Share on X · Email a friend
Phase III trial · breast cancer

The bispecific antibody anbenitamab improved control of breast cancer

In a phase III trial, people with HER2-positive advanced breast cancer received the bispecific antibody anbenitamab plus albumin-bound docetaxel or standard treatment. At 24 months, 58.5% versus 34.4% had no cancer growth or death.

Why it matters. A large, final-stage trial in breast cancer. This is the kind of result regulators use when deciding whether to approve a treatment.

The ASCO Post, 11 Nov 2026 · Phase III human clinical trial | 885 patients Worth sharing · Share on X · Email a friend
Research · lung cancer

TROP2 measure predicted outcomes with the antibody-drug conjugate datopotamab deruxtecan in lung cancer

Researchers studied people with nonsquamous lung cancer without actionable gene changes. A measure of TROP2 location in tumors predicted more time before cancer growth and longer lives with the antibody-drug conjugate datopotamab deruxtecan.

Why it matters. People with lung cancer may one day use this measure to learn whether they could have better outcomes with the ADC datopotamab deruxtecan. It studied patient records rather than testing a treatment.

Nature Medicine, 11 Nov 2026 · Human observational study
Phase III trial · lung cancer

Immunotherapy added to radiation did not help early-stage lung cancer

In 448 people with untreated, inoperable early-stage lung cancer, researchers added pembrolizumab immunotherapy to focused radiation. Time before cancer-related events was 31.2 months, versus 28.3 months with radiation alone, and side effects were greater.

“An interim analysis of the phase 3 (large late-stage) KEYNOTE-867 trial published by Jabbour et al in the Journal of Clinical Oncology did not appear to support the combination of stereotactic body radiotherapy (SBRT) and pembrolizumab in patients with unresected stage I or II non–small cell lung cancer. “[Event-free survival] and [overall survival] were not improved with the addition of pembrolizumab to SBRT, and the combination was associated with greater toxicity, compared with SBRT alone,” the investigators wrote.”

Why it matters. People with early-stage lung cancer who cannot have surgery may avoid adding immunotherapy to focused radiation, which did not improve outcomes and caused more side effects. Results from a large final-stage trial like this decide approvals.

The ASCO Post, 11 Nov 2026 · Phase III human clinical trial | 448 patients Worth sharing · Share on X · Email a friend
Phase II trial · ovarian cancer

The targeted drug risovalisib shrank ovarian cancer in a phase 2 trial

In a trial, 93 people with recurrent or persistent ovarian clear cell cancer took risovalisib. Tumors shrank in 35% of the 84 patients assessed.

“These results support risovalisib as a potential novel treatment option for PIK3CA-mutated ovarian clear cell carcinoma, a rare yet lethal cancer in dire need of additional treatment options.”

Why it matters. People with recurring ovarian clear cell cancer may have another treatment option in risovalisib. A larger trial usually comes before approval.

The Lancet Oncology, 10 Nov 2026 · Phase II human clinical trial | 93 patients Worth sharing · Share on X · Email a friend
Guideline · several cancer types

Guidelines recommend molecular testing for children with solid tumors

A cancer expert group reviewed 41 studies and developed recommendations for DNA and RNA sequencing and methylation testing when children are diagnosed or their cancer returns.

“Broad adoption of these recommendations may improve diagnostic precision, reduce variability in molecular testing, and increase opportunities for biomarker-directed therapy and clinical trial enrollment for children with cancer.”

Why it matters. Children with solid tumors could get more consistent testing that may help guide treatment and access to clinical trials. This is official guidance for doctors.

Clinical Cancer Research, 11 Nov 2026 · Clinical practice guideline

Deals and stopped trials

India

Worth watching